					Approved for use through 08/3	PTO/SB/21 (08-03) 30/2003. OMB 0651-0031	
Under the Pap	erwork Reduction Act of 1995	i, no person	is are required to respond to a collection	t and Tr p.of info	ademark Office; U.S. DEPAR ormation unless it displays a v	TMENT OF COMMERCE alid OMB control number.	
			Application Number	10/66	8,920		١
TRANSMITTAL			Filing Date	September 23, 2003		RECEIV	ED
FÖRM			First Named Inventor	ARNAIZ, Damian O. et al.		CENTRAL FAX	CENTER
(to be used for a	(to be used for all correspondence after initial filing)		Art Unit .	1614		MAD A 9	1,004
		Examiner Name	Not Yet Known		MAR 0 3	1 2004	
Total Number of Pages in This Submission 3		3	Attorney Docket Number	52340	DAUSM1	ACCIO	
,		ENC	LOSURES (Check all that	apply)		
Fee Trans	mittal Form		Drawing(s)		After Allowance to Technology C		
☐ Fe	e Attached		Licensing-related Papers		Appeal Commun		1
Amendme			Petition		Appeal Commun (Appeal Notice, Bo	ication to TC	·
After Final			Petition to Convert to a Provisional Application		Proprietary Infon	mation	
Aff	Affidavits/declaration(s)		Power of Attorney, Revocation Change of Correspondence Address	988	Status Letter		
Extension	Extension of Time Request		Terminal Disclaimer		Other Enclosure Identify below):	(s) (please	
Express Abandonment Request			Request for Refund		PTO-1449 Form		
Informatio	Information Disclosure Statement		CD, Number of CD(s)				<u>]</u> .
	Copy of Priority	Rema	rks				
Document	•	Submis	esion via Facsimile to: (703) 872-9	9306 T	C1600		
	to Missing Parts/ Application						1
	sponse to Missing Parts	If this f	ax has reached the wrong technol	ogy ce	nter, please call (510) 669	-4529. Thank You.	ŀ
ԱJ un	der 37 CFR 1.52 or 1.53	1	•				
		<u> </u>			· •		1
	SIGNA	TURE	OF APPLICANT, ATTORN	EY, C	RAGENT		
Firm or	Ronald S. Hermenau						
Individual name Signature							4
	Laral &	178	mena				4
Date	3/3/04			,	· · · · · · · · · · · · · · · · · · ·	- 	_]
	C	ERTIF	CATE OF TRANSMISSION	I/MAI	LING		\
I hereby certify the sufficient postage the date shown be	as first class mail in on e	being facs welope ac	imile transmitted to the USPTO or Idressed to: Commissioner for Pa	depos lents, f	ited with the United States 2.O. Box 1450, Alexandria	s Postal Service with , VA 22313-1450 on]
Turned on printed a	·						- ∤
Typed or printed r	Mary Ann	Flores					
Signature	Mar	S)	whites		Date MA	ARCh 3,2104)
process) an applicat gathering, preparing amount of time you r Trademark Office, U	ion. Confidentiality is governo , and aubmitting the complete require to completo this form .S. Department of Commerce	id by 35 U.S id application and/or sugg i. P.O. Box	Information is required to obtain or rota 5.C. 122 and 37 CFR 1.14. This collect on form to the USPTO. Time will vary di- estions for reducing this burden, sho DI 1450, Alexandria, VA 22313-1450, DI D. Box 1450, Alexandria, VA 223	tion is e ependin d be sei NOT S	stimated to 12 minutes to com g upon the Individual case, Ai nt to the Chief Information Off END FEES OR COMPLETED	nplete, including ny comments on the icer, U.S. Patent and	

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of ARNAIZ, Damian O. et al.

Group Art Unit: 1614

Application No.: 10/668,920

Examiner: Not Yet Known

Filed: September 23, 2003

Docket No. 52340AUSM1

For: Imidazolidinedione Analogs Useful as Anticoagulants and Antithrombotics

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 CFR §1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the reference cited on the attached form PTO-1449. Since this application was filed after June 30, 2003, a copy of the US Patent cited in this IDS has not been enclosed, per the waiver of the requirement under 37 CFR 1.98(a)(2)(i) published in the Official Gazette at 1276 OG 55. As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. §1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited reference of record in the above-identified application.

Respectfully Submitted,

Ronald S. Hermenau (Reg. No. 34,620)

Road of Hermen

Patent Attorney for Applicants

Date:

Berlex Biosciences 2600 Hilltop Drive P.O. Box 4099 Richmond, California 94804-0099 Telephone No. 510-669-4483 Facsimile No. 510-262-7095 Customer No. 27586

Forms/Pat/P7-27 [01/31/01]

Sheet 1 of 1 FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY, DOCKET NO. APPLICATION NO. PATENT AND TRADEMARK OFFICE (REV.7-80) 52340AUSM1 10/668,920 **APPLICANTS** INFORMATION DISCLOSURE STATEMENT ARNAIZ, Damian O. et al. (Use several sheets if necessary) FILING DATE GROUP ART UNIT September 23, 2003 1614 U.S. PATENT DOCUMENTS *EXAMINER INITIAL FILING DATE IF APPROPRIATE DOCUMENT NUMBER CLASS SUBCLASS US2002/0168700 11/14/02 Chi et al. 05/08/02 FOREIGN PATENT DOCUMENTS TRANSLATION DOCUMENT NUMBER DATE COUNTRY YES NO **EXAMINER** DATE CONSIDERED * EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant(s).